| Literature DB >> 36142061 |
Boyoung Park1, Yunsu Choi1, Jung Ho Kim2,3, Hye Seong4, Youn Jeong Kim5, Myungsun Lee6, Jaehyun Seong6, Shin-Woo Kim7, Joon Young Song4, Hee-Jung Choi8, Dae Won Park4, Hyo Youl Kim9, Jun Yong Choi2,3, Sang Il Kim10, Bo-Youl Choi1.
Abstract
The mortality rate and causes of death among individuals diagnosed with human immunodeficiency virus (HIV) infection in Korea were described and compared to those of the general population of Korea using a nationwide population-based claims database. We included 13,919 individuals aged 20-79 years newly diagnosed with HIV between 2004 and 2018. The patients' vital status and cause of death were linked until 31 December 2019. Standardized mortality ratios (SMRs) for all-cause death and specific causes of death were calculated. By the end of 2019, 1669 (12.0%) of the 13,919 HIV-infected participants had died. The survival probabilities of HIV-infected individuals at 1, 5, 10, and 15 years after diagnosis in Korea were 96.2%, 91.6%, 85.9%, and 79.6%, respectively. The main causes of death during the study period were acquired immunodeficiency syndrome (AIDS; 59.0%), non-AIDS-defining cancer (8.2%), suicide (7.4%), cardiovascular disease (4.9%), and liver disease (2.7%). The mortality rate of men and women infected with HIV was 5.60-fold (95% CI = 5.32-5.89) and 6.18-fold (95% CI = 5.30-7.09) that of men and women in the general population, respectively. After excluding deaths due to HIV, the mortality remained significantly higher, with an SMR of 2.16 (95% CI = 1.99-3.24) in men and 3.77 (95% CI = 3.06-4.48) in women. HIV-infected individuals had a higher overall mortality than the general population, with AIDS the leading cause of mortality. Additionally, mortality due to non-AIDS-related causes was higher in HIV-infected individuals.Entities:
Keywords: acquired immunodeficiency syndrome; human immunodeficiency virus; mortality; standardized mortality ratio
Mesh:
Year: 2022 PMID: 36142061 PMCID: PMC9517230 DOI: 10.3390/ijerph191811788
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Characteristics of human immunodeficiency virus (HIV)-infected people in Korea, 2004–2018.
| Total | Men | Women | ||
|---|---|---|---|---|
| Age at diagnosis | ||||
| Mean (standard deviation) | 40.3 (13.3) | 39.7 (13.0) | 44.9 (14.8) | <0.001 |
| 20–29 | 3617 (26%) | 3343 (26.8%) | 274 (18.8%) | <0.001 |
| 30–39 | 3642 (26.2%) | 3310 (26.6%) | 332 (22.8%) | |
| 40–49 | 3156 (22.7%) | 2894 (23.2%) | 262 (18%) | |
| 50–59 | 2185 (15.7%) | 1864 (15%) | 321 (22.1%) | |
| 60–69 | 960 (6.9%) | 782 (6.3%) | 178 (12.2%) | |
| 70+ | 359 (2.6%) | 271 (2.2%) | 88 (6%) | |
| Year of diagnosis | ||||
| 2004–2008 | 3778 (27.1%) | 3224 (25.9%) | 554 (38.1%) | <0.001 |
| 2009–2013 | 4481 (32.2%) | 4019 (32.2%) | 462 (31.8%) | |
| 2014–2018 | 5660 (40.7%) | 5221 (41.9%) | 439 (30.2%) | |
| Income | ||||
| Medical Aid | 620 (4.5%) | 508 (4.1%) | 112 (7.7%) | <0.001 |
| 1st–5th quartile | 3173 (22.8%) | 2815 (22.6%) | 358 (24.6%) | |
| 6th–10th quartile | 3221 (23.1%) | 2874 (23.1%) | 347 (23.8%) | |
| 11th–15th quartile | 2984 (21.4%) | 2716 (21.8%) | 268 (18.4%) | |
| 16th–20th quartile | 3707 (26.6%) | 3364 (27%) | 343 (23.6%) | |
| Missing | 214 (1.5%) | 187 (1.5%) | 27 (1.9%) | |
| AIDS-defining illness within 6 months of HIV diagnosis | ||||
| No | 11,823 (84.9%) | 10,512 (84.3%) | 1311 (90.1%) | <0.001 |
| Yes | 2096 (15.1%) | 1952 (15.7%) | 144 (9.9%) | |
| Highly active antiretroviral therapy | ||||
| Never | 1322 (9.5%) | 851 (6.8%) | 471 (32.4%) | <0.001 |
| Ever | 12,597 (90.5%) | 11,613 (93.2%) | 984 (67.6%) | |
AIDS, acquired immunodeficiency syndrome. 1 p-value for differences between men and women.
Mortality according to characteristics of human immunodeficiency virus (HIV)-infected individuals in Korea, 2004–2018: all-cause mortality, and mortality from acquired immunodeficiency syndrome (AIDS), cancer, AIDS-defining cancer, non-AIDS defining cancer, cardiovascular disease, liver disease, suicide, accident, other infections, and other causes.
| PY | All-Cause | AIDS | Total Cancer | AIDS-Defining Cancer | Non-AIDS Defining Cancer | Cardiovascular Disease | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | MR | N | MR | N | MR | N | MR | N | MR | N | MR | ||
| Total | 97,438.8 | 1669 | 1712.9 | 985 | 1010.9 | 161 | 165.2 | 24 | 24.6 | 137 | 140.6 | 82 | 84.2 |
| Sex | |||||||||||||
| Men | 85,613.9 | 1492 | 1742.7 | 916 | 1069.9 | 135 | 157.7 | 22 | 25.7 | 113 | 132 | 69 | 80.6 |
| Women | 11,824.9 | 177 | 1496.8 | 69 | 583.5 | 26 | 219.9 | 2 | 16.9 | 24 | 203 | 13 | 109.9 |
| Age at diagnosis | |||||||||||||
| 20–29 | 23,591.2 | 103 | 436.6 | 45 | 190.7 | 9 | 38.1 | 2 | 8.5 | 7 | 29.7 | 3 | 12.7 |
| 30–39 | 27,776.2 | 259 | 932.5 | 158 | 568.8 | 14 | 50.4 | 3 | 10.8 | 11 | 39.6 | 6 | 21.6 |
| 40–49 | 23,644.8 | 420 | 1776.3 | 279 | 1180 | 38 | 160.7 | 8 | 33.8 | 30 | 126.9 | 16 | 67.7 |
| 50–59 | 14,531.1 | 415 | 2855.9 | 272 | 1871.9 | 49 | 337.2 | 6 | 41.3 | 43 | 295.9 | 9 | 61.9 |
| 60–69 | 5931.1 | 289 | 4872.7 | 162 | 2731.4 | 30 | 505.8 | 4 | 67.4 | 26 | 438.4 | 19 | 320.3 |
| 70+ | 1964.1 | 183 | 9317.2 | 69 | 3513.1 | 21 | 1069.2 | 1 | 50.9 | 20 | 1018.3 | 29 | 1476.5 |
| Income | |||||||||||||
| Medical Aid | 4882.3 | 164 | 3359.1 | 90 | 1843.4 | 11 | 225.3 | 1 | 20.5 | 10 | 204.8 | 10 | 204.8 |
| 1st–5th quartile | 22,160.9 | 428 | 1931.3 | 263 | 1186.8 | 36 | 162.4 | 3 | 13.5 | 33 | 148.9 | 16 | 72.2 |
| 6th–10th quartile | 22,763.5 | 328 | 1440.9 | 186 | 817.1 | 30 | 131.8 | 3 | 13.2 | 27 | 118.6 | 23 | 101 |
| 11th–15th quartile | 21,170.6 | 321 | 1516.3 | 159 | 751 | 46 | 217.3 | 8 | 37.8 | 38 | 179.5 | 22 | 103.9 |
| 16th–20th quartile | 24,972.0 | 410 | 1641.8 | 274 | 1097.2 | 38 | 152.2 | 9 | 36 | 29 | 116.1 | 11 | 44 |
| Missing | 1489.5 | 18 | 1208.5 | 13 | 872.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AIDS-defining illness within 6 months of HIV diagnosis | |||||||||||||
| No | 78,523.0 | 1149 | 1463.3 | 589 | 750.1 | 135 | 171.9 | 16 | 20.4 | 119 | 151.5 | 70 | 89.1 |
| Yes | 18,915.8 | 520 | 2749 | 396 | 2093.5 | 26 | 137.5 | 8 | 42.3 | 18 | 95.2 | 12 | 63.4 |
| Highly active antiretroviral therapy | |||||||||||||
| Never | 10,589.9 | 347 | 3276.7 | 104 | 982.1 | 55 | 519.4 | 3 | 28.3 | 52 | 491 | 42 | 396.6 |
| Ever | 86,848.9 | 1322 | 1522.2 | 881 | 1014.4 | 106 | 122.1 | 21 | 24.2 | 85 | 97.9 | 40 | 46.1 |
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
| ||||
| Total | 97,438.8 | 45 | 46.2 | 124 | 127.3 | 37 | 38 | 35 | 35.9 | 200 | 205.3 | ||
| Sex | |||||||||||||
| Men | 85,613.9 | 39 | 45.6 | 116 | 135.5 | 35 | 40.9 | 26 | 30.4 | 156 | 182.2 | ||
| Women | 11,824.9 | 6 | 50.7 | 8 | 67.7 | 2 | 16.9 | 9 | 76.1 | 44 | 372.1 | ||
| Age at diagnosis | |||||||||||||
| 20–29 | 23,591.2 | 0 | 0 | 27 | 114.4 | 6 | 25.4 | 2 | 8.5 | 11 | 46.6 | ||
| 30–39 | 27,776.2 | 7 | 25.2 | 29 | 104.4 | 11 | 39.6 | 3 | 10.8 | 31 | 111.6 | ||
| 40–49 | 23,644.8 | 10 | 42.3 | 33 | 139.6 | 4 | 16.9 | 4 | 16.9 | 36 | 152.3 | ||
| 50–59 | 14,531.1 | 18 | 123.9 | 21 | 144.5 | 7 | 48.2 | 3 | 20.6 | 36 | 247.7 | ||
| 60–69 | 5931.1 | 7 | 118 | 12 | 202.3 | 3 | 50.6 | 12 | 202.3 | 44 | 741.9 | ||
| 70+ | 1964.1 | 3 | 152.7 | 2 | 101.8 | 6 | 305.5 | 11 | 560.1 | 42 | 2138.4 | ||
| Income | |||||||||||||
| Medical Aid | 4882.3 | 6 | 122.9 | 11 | 225.3 | 4 | 81.9 | 3 | 61.4 | 29 | 594 | ||
| 1st–5th quartile | 22,160.9 | 12 | 54.1 | 32 | 144.4 | 10 | 45.1 | 11 | 49.6 | 48 | 216.6 | ||
| 6th–10th quartile | 22,763.5 | 3 | 13.2 | 28 | 123 | 7 | 30.8 | 7 | 30.8 | 44 | 193.3 | ||
| 11th–15th quartile | 21,170.6 | 15 | 70.9 | 24 | 113.4 | 9 | 42.5 | 7 | 33.1 | 39 | 184.2 | ||
| 16th–20th quartile | 24,972.0 | 9 | 36 | 27 | 108.1 | 7 | 28 | 7 | 28 | 37 | 148.2 | ||
| Missing | 1489.5 | 0 | 0 | 2 | 134.3 | 0 | 0 | 0 | 0 | 3 | 201.4 | ||
| AIDS-defining illness within 6 months of HIV diagnosis | |||||||||||||
| No | 78,523.0 | 40 | 50.9 | 92 | 117.2 | 30 | 38.2 | 28 | 35.7 | 165 | 210.1 | ||
| Yes | 18,915.8 | 5 | 26.4 | 32 | 169.2 | 7 | 37 | 7 | 37 | 35 | 185 | ||
| Highly active antiretroviral therapy | |||||||||||||
| Never | 10,589.9 | 23 | 217.2 | 21 | 198.3 | 9 | 85 | 19 | 179.4 | 74 | 698.8 | ||
| Ever | 86,848.9 | 22 | 25.3 | 103 | 118.6 | 28 | 32.2 | 16 | 18.4 | 126 | 145.1 | ||
MR, mortality rate; PY, person-year. The 95% confidence intervals of mortality rates are presented in Table S4.
Figure 1Kaplan–Meier survival estimates by year of diagnosis and years since diagnosis.
Figure 2Distribution of the causes of death among individuals with human immunodeficiency virus (HIV) in Korea, 2004–2018.
Standardized mortality ratios (SMRs) of human immunodeficiency virus (HIV)-infected individuals in Korea according to sex and cause of death, 2004–2018.
| Observed Deaths | Expected Deaths | SMR | ||
|---|---|---|---|---|
| Men | ||||
| All-cause | 1492 | 266.07 | 5.60 (5.32–5.89) | <0.001 |
| All-cause except AIDS | 576 | 265.72 | 2.16 (1.99–2.34) | <0.001 |
| All cancers | 135 | 83.59 | 1.62 (1.34–1.88) | <0.001 |
| AIDS-defining cancers | 22 | 2.51 | 8.74 (5.09–12.40) | <0.001 |
| Non-AIDS defining cancers | 113 | 81.07 | 1.39 (1.14–1.65) | 0.003 |
| Cardiovascular disease | 69 | 42.18 | 1.61 (1.23–1.99) | 0.002 |
| Liver disease | 39 | 17.11 | 2.28 (1.56–2.99) | 0.001 |
| Suicide | 116 | 32.53 | 3.56 (2.92–4.21) | <0.001 |
| Accident | 35 | 31.83 | 1.10 (0.73–1.45) | 0.592 |
| Other infections | 26 | 10.77 | 2.41 (1.49–3.34) | 0.003 |
| Others | 156 | 47.43 | 3.29 (2.77–3.81) | <0.001 |
| Women | ||||
| All-cause | 177 | 28.64 | 6.18 (5.30–7.09) | <0.001 |
| All-cause except AIDS | 108 | 28.63 | 3.77 (3.06–4.48) | <0.001 |
| All cancers | 26 | 10.56 | 2.46 (1.51–3.41) | 0.003 |
| AIDS-defining cancers | 2 | 0.79 | 2.54 (0.00–6.06) | 0.391 |
| Non-AIDS defining cancers | 24 | 9.78 | 2.45 (1.47–3.44) | 0.004 |
| Cardiovascular disease | 13 | 6.07 | 2.14 (0.98–3.31) | 0.054 |
| Liver disease | 6 | 0.65 | 9.17 (1.83–16.51) | 0.029 |
| Suicide | 8 | 2.23 | 3.58 (1.10–6.06) | 0.042 |
| Accident | 2 | 1.7 | 1.18 (0.00–2.81) | 0.829 |
| Other infections | 9 | 1.26 | 7.15 (2.48–11.82) | 0.01 |
| Others | 44 | 6.17 | 7.13 (5.02–9.24) | <0.001 |
AIDS, acquired immunodeficiency syndrome.